# Chemotherapy and the somatic mutation burden of sperm

**Authors:** Shany Picciotto, Camilo Arenas-Gallo, Amos Toren, Ruty Mehrian-Shai, Bryan Daly, Stephen Rhodes, Megan Prunty, Ruolin Liu, Anyull Bohorquez, Marta Grońska-Pęski, Shana Melanaphy, Pamela Callum, Emilie Lassen, Anne-Bine Skytte, Rebecca C. Obeng, Christopher Barbieri, Molly Gallogly, Brenda Cooper, Katherine Daunov, Lydia Beard, Koen van Besien, Joshua Halpern, Quintin Pan, Gilad D. Evrony, Viktor A. Adalsteinsson, Jonathan E. Shoag

PMC · DOI: 10.1172/jci.insight.188175 · JCI Insight · 2025-05-13

## TL;DR

Chemotherapy increases mutation rates in human and mouse sperm, with implications for fertility decisions and genetic counseling.

## Contribution

This study is the first to show chemotherapy-induced mutations in sperm and other tissues using high-fidelity sequencing in humans and mice.

## Key findings

- Sperm from chemotherapy-treated men had elevated mutation burdens compared to controls and age-based expectations.
- One patient had over a 10-fold increase in mutations, also observed in saliva, blood, liver, and mouse models.
- Cancer therapies like cisplatin are linked to increased mutation burdens in multiple tissues.

## Abstract

Many chemotherapeutic agents impair cancer growth by inducing DNA damage. The impact of these agents on mutagenesis in normal cells, including sperm, is largely unknown. Here, we applied high-fidelity duplex sequencing to 94 samples from 36 individuals exposed to diverse chemotherapies and 32 controls. We found that in many of the sperm samples from men exposed to chemotherapy, the mutation burden was elevated as compared with controls and the expected burden based on trio studies, with 1 patient having a more than 10-fold increase over that expected for age. Saliva from this same individual also had a markedly higher mutation burden. We then validated this finding using other tissues, also finding an increased mutation burden in the blood and liver of many patients exposed to chemotherapy as compared with unexposed controls. Similarly, mice treated with 3 cycles of cisplatin had an increased mutation burden in sperm but also in the liver and hematopoietic progenitor cells. These results suggest an association between cancer therapies and mutation burden, with implications for counseling patients with cancer considering banking sperm before therapy and for cancer survivors considering the trade-offs of using banked sperm as compared with conceiving naturally.

Chemotherapy exposure is associated with an increase in new mutations in sperm in humans and mice.

## Linked entities

- **Chemicals:** cisplatin (PubChem CID 5460033)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Diseases:** cancer (MESH:D009369)
- **Chemicals:** cisplatin (MESH:D002945)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12220962/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12220962/full.md

## References

58 references — full list in the complete paper: https://tomesphere.com/paper/PMC12220962/full.md

---
Source: https://tomesphere.com/paper/PMC12220962